EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of Quinoline-Based Hydroxamic Acid Derivatives as Dual DNMT and HDAC Inhibitors with Potent Anti-Breast Cancer Activity

Huaxin Lin, Wenwen Zheng, Zigao Yuan iD, Lulu Li, Yuling Tan, Wenjun Huang, Jiaqi Liu, Zixuan Qiu, Qinyuan Li, Bizhu Chu iD, Yuyang Jiang iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Huaxin Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Chinese Medicine Ingredients and Gut Microbiomics, School of Pharmacy, Shenzhen University Medical School, She…. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Quinolines, Breast Neoplasms, Drug Design. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Stable Support Project of Shenzhen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) play complementary roles in epigenetic regulation, and their simultaneous inhibition is a promising strategy for cancer therapy. Herein, we report the design, synthesis, and biological evaluation of a series of quinoline-based hydroxamic acid derivatives as dual DNMT and HDAC inhibitors. Notably, compound Y7 emerged as the most potent dual-target inhibitor, with IC50 values of 365 and 0.20 nM against DNMT1 and HDAC1, respectively. Furthermore, Y7 exhibited significantly enhanced antitumor efficacy compared with that of decitabine–SAHA combination in breast cancer cells. The results of in vivo experiments showed that Y7 markedly reduced tumor growth in both xenograft and transgenic breast cancer mouse models, presenting superior efficacy than the decitabine–SAHA combination without detectable toxicity. Altogether, these results present Y7 as a promising dual DNMT and HDAC inhibitor with the potential for further development as a therapeutic agent for breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsQuinolinesBreast NeoplasmsDrug DesignHydroxamic AcidsAntineoplastic AgentsDNA (Cytosine-5-)-MethyltransferasesHumansAnimalsFemaleMiceDNA (Cytosine-5-)-Methyltransferase 1Cell Line, TumorStructure-Activity RelationshipCell ProliferationXenograft Model Antitumor AssaysHistone Deacetylase 1Mice, Nude

Substanzen

Histone Deacetylase InhibitorsQuinolinesHydroxamic AcidsAntineoplastic AgentsDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanDNA (Cytosine-5-)-MethyltransferasesHistone Deacetylase 1quinoline

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Chinese Medicine Ingredients and Gut Microbiomics, School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.
  • Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University Medical…
  • State Key Laboratory of Chemical Oncogenomics, Tsinghua Shenzhen International Graduate School, Shenzhen 518055, China.
  • Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China.
  • School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.

ORCID-Profile: Zigao Yuan, Bizhu Chu, Yuyang Jiang

Förderung

  • National Natural Science Foundation of China
  • Stable Support Project of Shenzhen

Zitieren

APA

Lin, H., Zheng, W., Yuan, Z., Li, L., Tan, Y., Huang, W., Liu, J., Qiu, Z., Li, Q., Chu, B., & Jiang, Y. (2025). Design, Synthesis, and Biological Evaluation of Quinoline-Based Hydroxamic Acid Derivatives as Dual DNMT and HDAC Inhibitors with Potent Anti-Breast Cancer Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01092

Vancouver

Lin H, Zheng W, Yuan Z, Li L, Tan Y, Huang W, et al. Design, Synthesis, and Biological Evaluation of Quinoline-Based Hydroxamic Acid Derivatives as Dual DNMT and HDAC Inhibitors with Potent Anti-Breast Cancer Activity. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01092

BibTeX
@article{Lin2025,
  author = {Lin, Huaxin and Zheng, Wenwen and Yuan, Zigao and Li, Lulu and Tan, Yuling and Huang, Wenjun and Liu, Jiaqi and Qiu, Zixuan and Li, Qinyuan and Chu, Bizhu and Jiang, Yuyang},
  title = {Design, Synthesis, and Biological Evaluation of Quinoline-Based Hydroxamic Acid Derivatives as Dual DNMT and HDAC Inhibitors with Potent Anti-Breast Cancer Activity},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01092}
}
Kostenlos starten →